<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920816</url>
  </required_header>
  <id_info>
    <org_study_id>A4061051</org_study_id>
    <secondary_id>2010-018585-23</secondary_id>
    <nct_id>NCT00920816</nct_id>
  </id_info>
  <brief_title>Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer</brief_title>
  <official_title>Ag-013736 (Axitinib) For The Treatment Of Metastatic Renal Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in
      delaying tumor progression in patients with metastatic renal cell cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 25, 2009</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Actual">July 27, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS): First-Line Participants</measure>
    <time_frame>Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)</time_frame>
    <description>Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease [PD]), or from adverse event (AE) data (where outcome was &quot;Death&quot;). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is &gt;= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS): Second-Line Participants</measure>
    <time_frame>Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)</time_frame>
    <description>Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease [PD]), or from adverse event (AE) data (where outcome was &quot;Death&quot;). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is &gt;= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Objective Response (OR): First-Line Participants</measure>
    <time_frame>Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)</time_frame>
    <description>Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Objective Response (OR): Second-Line Participants</measure>
    <time_frame>Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)</time_frame>
    <description>Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR): First-Line Participants</measure>
    <time_frame>Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)</time_frame>
    <description>Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR): Second-Line Participants</measure>
    <time_frame>Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)</time_frame>
    <description>Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS): First-Line Participants</measure>
    <time_frame>Baseline until death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)</time_frame>
    <description>Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS): Second-Line Participants</measure>
    <time_frame>Baseline until death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)</time_frame>
    <description>Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): First-Line Participants</measure>
    <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)</time_frame>
    <description>FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): Second-Line Participants</measure>
    <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)</time_frame>
    <description>FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): First-Line Participants</measure>
    <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)</time_frame>
    <description>FKSI-DRS: subset of FKSI which is FACT-Kidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): Second-Line Participants</measure>
    <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)</time_frame>
    <description>FKSI-DRS: subset of FKSI which is FACT-Kidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).</description>
  </other_outcome>
  <other_outcome>
    <measure>Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: First-Line Participants</measure>
    <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
  </other_outcome>
  <other_outcome>
    <measure>Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: Second-Line Participants</measure>
    <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
  </other_outcome>
  <other_outcome>
    <measure>Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): First-Line Participants</measure>
    <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.</description>
  </other_outcome>
  <other_outcome>
    <measure>Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): Second-Line Participants</measure>
    <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">492</enrollment>
  <condition>Kidney Neoplasms</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib (AG-013736)</intervention_name>
    <description>axitinib will be given at a starting dose of 5 mg BID with continuous dosing</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>sorafenib will be given at a dose of 400 mg BID continuous dosing</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented metastatic renal cell cancer with a component of clear cell
             histology.

          -  Evidence of measurable disease.

          -  Patients with mRCC must have received no prior systemic first-line therapy or must
             have progressive disease per RECIST (version 1.0) after one prior systemic first line
             regimen for metastatic disease containing sunitinib, cytokine(s), or both.

        Exclusion Criteria:

          -  Prior treatment for metastatic renal cell cancer with more that one systemic first
             line therapy.

          -  Major surgery less that 4 weeks or radiation less than 2 weeks of starting study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Medical Specialities</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Specialties</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Central Indiana Cancer Centers</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Central Indiana Cancer Centers</name>
      <address>
        <city>Fishers</city>
        <state>Indiana</state>
        <zip>46037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Central Indiana Cancer Centers</name>
      <address>
        <city>Greenfield</city>
        <state>Indiana</state>
        <zip>46140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Central Indiana Cancer Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Central Indiana Cancer Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Cancer Associates</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology West Region</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Associates of Northern NJ, PA</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Associates of Northern NJ, PA</name>
      <address>
        <city>Parsippany</city>
        <state>New Jersey</state>
        <zip>07054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, PC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, PC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, PC</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <zip>12110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, PC</name>
      <address>
        <city>Rexford</city>
        <state>New York</state>
        <zip>12148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, PC</name>
      <address>
        <city>Troy</city>
        <state>New York</state>
        <zip>12180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Hematology Oncology Associates</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Hematology Oncology Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Hematology Oncology Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, PC</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center, Penn State Cancer Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina University Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer Center</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702-1449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Fort Worth 12th Avenue</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Southwest Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Products Center (IPC)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76177</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Products Center (lPC)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76177</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology Research and Clinical Pharmacy</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76177</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Grapevine</name>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <zip>76051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>Kerrville</city>
        <state>Texas</state>
        <zip>78028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- McAllen South Second Street</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Midland Allison Cancer Center</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258-3912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Deke Slayton Cancer Center</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598-4420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Weslaco</name>
      <address>
        <city>Weslaco</city>
        <state>Texas</state>
        <zip>78596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Christiansburg</city>
        <state>Virginia</state>
        <zip>24073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Low Moor</city>
        <state>Virginia</state>
        <zip>24457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Wytheville</city>
        <state>Virginia</state>
        <zip>24382</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, PC</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, PC</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Medical Center</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Oncology</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology, University Hospital Center Sarajevo</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Center Tuzla, Clinic for Oncology, Hematology and Radiotherapy</name>
      <address>
        <city>Tuzla</city>
        <zip>75000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spetsializirana Bolnitsa za Aktivno Lechenie po Onkologiya, EAD, Klinika po Himioterapiya</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBALOZ D-r Marko Markov-Varna</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico Oncologico del Sur</name>
      <address>
        <city>Temuco</city>
        <state>Cautin</state>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico Oncologico del Sur</name>
      <address>
        <city>Temuco</city>
        <state>IX Region</state>
        <zip>4810561</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Terapias Oncologicas Providencia</name>
      <address>
        <city>Providencia</city>
        <state>Santiago</state>
        <zip>7501088</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Office</name>
      <address>
        <city>Santiago</city>
        <zip>RM 8360160</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute and Hospital ,Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Haidian District</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fuzhou General Hospital, PLA Nanjing Military Area Command</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guang DONG</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Department, Sun Yet-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Bayi Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Oncology Department, Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin Provincial Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Department, The First Affiliated Hospital, China Medical University</name>
      <address>
        <city>Shen Yang</city>
        <state>LIAO NING Province</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital, The Fourth Military Medical University,Oncology Department</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Department, Renji Hospital,Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Urology,Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital/Department of Renal Cancer and Melanoma</name>
      <address>
        <city>Beijing</city>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South-Western Hospital, 3rd Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University, Cancer Hospital, Department of Urology</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Oncology Hospital,biology treatment department</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Department, The Second Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <zip>300211</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BIBI General Hospital and Cancer Centre,</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500024</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinmaya Mission Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560038</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sri Venkateshwara Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NU Hospitals</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Clinic and Hospitals</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shatabdi Superspeciality Hospital</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422 005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Curie Manavata Cancer Centre</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital and Research Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahyadri Speciality Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Mexico O.D.</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hemato-Oncologico Privado</name>
      <address>
        <city>Toluca</city>
        <state>Estado DE Mexico</state>
        <zip>50080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centenario Hospital Miguel Hidalgo</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oaxaca Site Management Organization</name>
      <address>
        <city>Oaxaca</city>
        <zip>68000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rm. 3227 Doctors Clinic, Annex II Bldg., National Kidney &amp; Transplant Institute</name>
      <address>
        <city>Quezon City</city>
        <state>Diliman</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Lukes Medical Center</name>
      <address>
        <city>Quezon City</city>
        <state>Metro Manila</state>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the East Ramon Magsaysay Memorial Medical Center</name>
      <address>
        <city>Quezon City</city>
        <state>Metro Manila</state>
        <zip>1113</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makati Medical Center</name>
      <address>
        <city>Makati City</city>
        <zip>1200</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Room 805, Committee on Research Room, Manila Doctors Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncomed SRL</name>
      <address>
        <city>Timisoara</city>
        <state>JUD. Timis</state>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic &quot;Prof.Dr.I.Chiricuta&quot; Cluj-Napoca</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic ''Prof.Dr. I. Chiricuta'' Cluj Napoca</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Healthcare Institution Oncology Clinical Dispensary #1</name>
      <address>
        <city>Moscow</city>
        <zip>105005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.A. Herzen Moscow Oncology Research Institute,</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBU RO &quot;Ryazan Regional Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Ryazan</city>
        <zip>390011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution Ryazan Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Ryazan</city>
        <zip>390011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGBOU VO &quot;Ryazan State Medical University named after academician I.P.Pavlov&quot;</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGBOU VO &quot;First Saint-Petersburg State Medical University n.a. I.P.Pavlov&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of the Ministry of Health of Bashkortostan Republic</name>
      <address>
        <city>Ufa</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GVI Oncology</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6045</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MI Dnipropetrovsk Regional Clinical Hospital n a I.I. Mechnikov</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv Regional Clinical Center of Urology and Nephrology</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Enterprise &quot;Institute of Urology of NAMS of Ukraine&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv State Oncologic Regional Treatment and Diagnostic Center</name>
      <address>
        <city>Lviv</city>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI &quot;Zaporizhzhya Medical Academy of Postgraduate Education of the Ministry of Health of Ukraine&quot;</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69040</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>China</country>
    <country>India</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4061051&amp;StudyName=Axitinib%20%28AG-013736%29%20For%20the%20Treatment%20of%20Metastatic%20Renal%20Cell%20Cancer</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2009</study_first_submitted>
  <study_first_submitted_qc>June 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2009</study_first_posted>
  <results_first_submitted>July 26, 2013</results_first_submitted>
  <results_first_submitted_qc>December 31, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2014</results_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Axitinib in First &amp; Second Line Treatment of Patients With Metastatic Renal Cell Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First-line participants included all treatment-naive participants with metastatic renal cell cancer (mRCC) from global and second-line participants included all previously-treated Asian participants with mRCC.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Axitinib (First-line Participants)</title>
          <description>Participants with no prior systemic first-line therapy received axitinib (AG-013736) tablet at a starting dose of 5 milligram (mg) orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Sorafenib (First-line Participants)</title>
          <description>Participants with no prior systemic first-line therapy received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Axitinib (Second-line Participants)</title>
          <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Sorafenib (Second-line Participants)</title>
          <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="69"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Objective progression or relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Axitinib (First-line Participants)</title>
          <description>Participants with no prior systemic first-line therapy received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Sorafenib (First-line Participants)</title>
          <description>Participants with no prior systemic first-line therapy received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Axitinib (Second-line Participants)</title>
          <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Sorafenib (Second-line Participants)</title>
          <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="192"/>
            <count group_id="B2" value="96"/>
            <count group_id="B3" value="135"/>
            <count group_id="B4" value="69"/>
            <count group_id="B5" value="492"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than (&lt;) 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to (&gt;=) 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS): First-Line Participants</title>
        <description>Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease [PD]), or from adverse event (AE) data (where outcome was &quot;Death&quot;). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is &gt;= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.</description>
        <time_frame>Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)</time_frame>
        <population>Full analysis set (FAS) included all treatment-naive participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS): First-Line Participants</title>
          <description>Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease [PD]), or from adverse event (AE) data (where outcome was &quot;Death&quot;). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is &gt;= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.</description>
          <population>Full analysis set (FAS) included all treatment-naive participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="7.2" upper_limit="12.1"/>
                    <measurement group_id="O2" value="6.5" lower_limit="4.7" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>First-line participants: hazard ratio was stratified by eastern cooperative oncology group (ECOG) performance status (0 versus 1).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.767</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.559</ci_lower_limit>
            <ci_upper_limit>1.053</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS): Second-Line Participants</title>
        <description>Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease [PD]), or from adverse event (AE) data (where outcome was &quot;Death&quot;). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is &gt;= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.</description>
        <time_frame>Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)</time_frame>
        <population>FAS included all previously-treated Asian participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS): Second-Line Participants</title>
          <description>Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease [PD]), or from adverse event (AE) data (where outcome was &quot;Death&quot;). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is &gt;= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.</description>
          <population>FAS included all previously-treated Asian participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="4.7" upper_limit="9.1"/>
                    <measurement group_id="O2" value="4.8" lower_limit="3.0" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Second-line participants: hazard ratio was stratified by eastern cooperative oncology group (ECOG) performance status (0 versus 1) and prior treatment (sunitinib versus cytokine-containing regimen).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.731</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.506</ci_lower_limit>
            <ci_upper_limit>1.058</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Objective Response (OR): First-Line Participants</title>
        <description>Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.</description>
        <time_frame>Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)</time_frame>
        <population>FAS included all treatment-naive participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Objective Response (OR): First-Line Participants</title>
          <description>Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.</description>
          <population>FAS included all treatment-naive participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" lower_limit="25.7" upper_limit="39.4"/>
                    <measurement group_id="O2" value="14.6" lower_limit="8.2" upper_limit="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Objective Response (OR): Second-Line Participants</title>
        <description>Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.</description>
        <time_frame>Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)</time_frame>
        <population>FAS included all previously-treated Asian participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Objective Response (OR): Second-Line Participants</title>
          <description>Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.</description>
          <population>FAS included all previously-treated Asian participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="16.8" upper_limit="31.8"/>
                    <measurement group_id="O2" value="10.1" lower_limit="4.2" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DR): First-Line Participants</title>
        <description>Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.</description>
        <time_frame>Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)</time_frame>
        <population>DR was calculated for the subgroup of participants from the FAS treatment-naive population, with a confirmed objective tumor response (CR or PR).</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DR): First-Line Participants</title>
          <description>Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.</description>
          <population>DR was calculated for the subgroup of participants from the FAS treatment-naive population, with a confirmed objective tumor response (CR or PR).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" lower_limit="11.0">Upper limit of CI was not estimable because participants were still responding to medication as the study was ongoing.</measurement>
                    <measurement group_id="O2" value="14.3" lower_limit="11.3">Upper limit of CI was not estimable because participants were still responding to medication as the study was ongoing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DR): Second-Line Participants</title>
        <description>Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.</description>
        <time_frame>Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)</time_frame>
        <population>DR was calculated for the subgroup of participants from the FAS previously-treated population, with a confirmed objective tumor response (CR or PR).</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DR): Second-Line Participants</title>
          <description>Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.</description>
          <population>DR was calculated for the subgroup of participants from the FAS previously-treated population, with a confirmed objective tumor response (CR or PR).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="12.5">Median was not estimable because participants were still responding to medication as the study was ongoing.</measurement>
                    <measurement group_id="O2" value="8.7" lower_limit="4.1">Upper limit of CI was not estimable because participants were still responding to medication as the study was ongoing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS): First-Line Participants</title>
        <description>Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).</description>
        <time_frame>Baseline until death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)</time_frame>
        <population>FAS included all treatment-naive participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS): First-Line Participants</title>
          <description>Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).</description>
          <population>FAS included all treatment-naive participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="18.1">Median time was not reachable as data was not matured at the time of the analysis as the study was ongoing.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="18.1">Median time was not reachable as data was not matured at the time of the analysis as the study was ongoing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS): Second-Line Participants</title>
        <description>Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).</description>
        <time_frame>Baseline until death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)</time_frame>
        <population>FAS included all previously-treated Asian participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS): Second-Line Participants</title>
          <description>Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).</description>
          <population>FAS included all previously-treated Asian participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" lower_limit="14.8">Upper limit of the CI was not reachable as data was not matured at the time of the analysis as the study was ongoing.</measurement>
                    <measurement group_id="O2" value="18.1" lower_limit="12.1">Upper limit of the CI was not reachable as data was not matured at the time of the analysis as the study was ongoing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): First-Line Participants</title>
        <description>FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).</description>
        <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)</time_frame>
        <population>FAS treatment-naive population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): First-Line Participants</title>
          <description>FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).</description>
          <population>FAS treatment-naive population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1 D1 (n= 183, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.869" spread="8.117"/>
                    <measurement group_id="O2" value="43.865" spread="6.723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (n= 176, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.328" spread="7.630"/>
                    <measurement group_id="O2" value="43.969" spread="6.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (n= 164, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.366" spread="7.192"/>
                    <measurement group_id="O2" value="43.345" spread="6.878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (n= 156, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.932" spread="7.566"/>
                    <measurement group_id="O2" value="42.926" spread="7.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (n= 153, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.211" spread="7.578"/>
                    <measurement group_id="O2" value="44.022" spread="6.714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C6 D1 (n= 141, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.787" spread="8.098"/>
                    <measurement group_id="O2" value="42.344" spread="6.685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (n= 139, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.474" spread="7.926"/>
                    <measurement group_id="O2" value="43.446" spread="6.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C8 D1 (n= 131, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.534" spread="7.510"/>
                    <measurement group_id="O2" value="44.077" spread="6.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (n= 126, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.778" spread="8.229"/>
                    <measurement group_id="O2" value="44.051" spread="7.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C10 D1 (n= 122, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.120" spread="7.966"/>
                    <measurement group_id="O2" value="44.018" spread="6.751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (n= 114, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.264" spread="7.837"/>
                    <measurement group_id="O2" value="45.000" spread="6.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C12 D1 (n= 105, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.962" spread="7.243"/>
                    <measurement group_id="O2" value="45.318" spread="6.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C13 D1 (n= 99, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.141" spread="7.289"/>
                    <measurement group_id="O2" value="45.787" spread="6.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C14 D1 (n= 95, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.789" spread="7.985"/>
                    <measurement group_id="O2" value="45.459" spread="6.535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C15 D1 (n= 85, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.176" spread="8.055"/>
                    <measurement group_id="O2" value="45.514" spread="5.914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C16 D1 (n= 82, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.232" spread="7.515"/>
                    <measurement group_id="O2" value="46.000" spread="5.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C17 D1 (n= 78, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.897" spread="8.456"/>
                    <measurement group_id="O2" value="46.400" spread="6.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C18 D1 (n= 71, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.761" spread="8.019"/>
                    <measurement group_id="O2" value="45.357" spread="6.983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C19 D1 (n= 57, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.737" spread="7.413"/>
                    <measurement group_id="O2" value="45.583" spread="7.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C20 D1 (n= 45, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.733" spread="7.605"/>
                    <measurement group_id="O2" value="44.333" spread="7.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C21 D1 (n= 36, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.417" spread="6.240"/>
                    <measurement group_id="O2" value="43.500" spread="7.687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C22 D1 (n= 23, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.000" spread="5.985"/>
                    <measurement group_id="O2" value="45.833" spread="5.937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C23 D1 (n= 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.571" spread="6.357"/>
                    <measurement group_id="O2" value="45.714" spread="6.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment (n= 72, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.052" spread="9.109"/>
                    <measurement group_id="O2" value="39.524" spread="8.896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (n= 41, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.683" spread="11.132"/>
                    <measurement group_id="O2" value="40.038" spread="9.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): Second-Line Participants</title>
        <description>FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).</description>
        <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)</time_frame>
        <population>FAS previously-treated Asian population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): Second-Line Participants</title>
          <description>FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).</description>
          <population>FAS previously-treated Asian population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1 D1 (n= 134, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.753" spread="6.692"/>
                    <measurement group_id="O2" value="47.470" spread="7.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (n= 127, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.217" spread="7.028"/>
                    <measurement group_id="O2" value="45.045" spread="7.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (n= 124, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.968" spread="7.237"/>
                    <measurement group_id="O2" value="45.684" spread="7.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (n= 116, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.060" spread="8.040"/>
                    <measurement group_id="O2" value="45.792" spread="7.762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (n= 111, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.775" spread="7.797"/>
                    <measurement group_id="O2" value="46.125" spread="7.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C6 D1 (n= 108, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.407" spread="7.274"/>
                    <measurement group_id="O2" value="46.341" spread="7.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (n= 100, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.709" spread="8.263"/>
                    <measurement group_id="O2" value="45.053" spread="7.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C8 D1 (n= 89, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.169" spread="7.609"/>
                    <measurement group_id="O2" value="45.676" spread="9.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (n= 82, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.829" spread="7.442"/>
                    <measurement group_id="O2" value="45.970" spread="8.487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C10 D1 (n= 74, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.608" spread="8.299"/>
                    <measurement group_id="O2" value="46.148" spread="8.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (n= 66, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.833" spread="7.599"/>
                    <measurement group_id="O2" value="47.227" spread="6.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C12 D1 (n= 59, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.797" spread="6.967"/>
                    <measurement group_id="O2" value="48.091" spread="6.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C13 D1 (n= 55, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.727" spread="7.307"/>
                    <measurement group_id="O2" value="47.600" spread="5.762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C14 D1 (n= 50, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.740" spread="7.094"/>
                    <measurement group_id="O2" value="49.133" spread="5.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C15 D1 (n= 44, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.023" spread="6.297"/>
                    <measurement group_id="O2" value="49.308" spread="4.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C16 D1 (n= 38, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.184" spread="6.186"/>
                    <measurement group_id="O2" value="50.500" spread="3.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C17 D1 (n= 33, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.909" spread="6.866"/>
                    <measurement group_id="O2" value="49.000" spread="5.869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C18 D1 (n= 29, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.138" spread="6.791"/>
                    <measurement group_id="O2" value="49.125" spread="5.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C19 D1 (n= 22, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.636" spread="5.206"/>
                    <measurement group_id="O2" value="48.571" spread="7.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C20 D1 (n= 21, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.810" spread="6.478"/>
                    <measurement group_id="O2" value="50.500" spread="4.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C21 D1 (n= 16, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.188" spread="5.588"/>
                    <measurement group_id="O2" value="50.000" spread="5.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment (n= 37, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.432" spread="9.188"/>
                    <measurement group_id="O2" value="42.889" spread="8.846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (n= 13, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.385" spread="7.795"/>
                    <measurement group_id="O2" value="38.583" spread="11.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): First-Line Participants</title>
        <description>FKSI-DRS: subset of FKSI which is FACTKidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).</description>
        <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)</time_frame>
        <population>FAS treatment-naive population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): First-Line Participants</title>
          <description>FKSI-DRS: subset of FKSI which is FACTKidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).</description>
          <population>FAS treatment-naive population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1 D1 (n= 183, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.691" spread="5.392"/>
                    <measurement group_id="O2" value="29.653" spread="4.699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (n= 176, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.728" spread="4.581"/>
                    <measurement group_id="O2" value="29.963" spread="3.817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (n= 164, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.171" spread="4.093"/>
                    <measurement group_id="O2" value="29.750" spread="4.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (n= 156, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.577" spread="4.305"/>
                    <measurement group_id="O2" value="29.642" spread="4.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (n= 153, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.020" spread="4.257"/>
                    <measurement group_id="O2" value="30.255" spread="3.668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C6 D1 (n= 141, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.574" spread="4.674"/>
                    <measurement group_id="O2" value="29.153" spread="4.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (n= 139, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.568" spread="4.548"/>
                    <measurement group_id="O2" value="29.523" spread="4.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C8 D1 (n= 131, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.557" spread="4.308"/>
                    <measurement group_id="O2" value="30.296" spread="3.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (n= 126, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.817" spread="4.665"/>
                    <measurement group_id="O2" value="30.186" spread="4.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C10 D1 (n= 122, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.057" spread="4.484"/>
                    <measurement group_id="O2" value="30.364" spread="4.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (n= 114, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.146" spread="4.207"/>
                    <measurement group_id="O2" value="30.688" spread="3.926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C12 D1 (n= 105, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.648" spread="3.752"/>
                    <measurement group_id="O2" value="30.727" spread="3.896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C13 D1 (n= 99, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.545" spread="4.056"/>
                    <measurement group_id="O2" value="31.483" spread="3.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C14 D1 (n= 95, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.579" spread="4.186"/>
                    <measurement group_id="O2" value="31.027" spread="3.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C15 D1 (n= 85, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.859" spread="4.438"/>
                    <measurement group_id="O2" value="30.730" spread="3.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C16 D1 (n= 82, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.683" spread="4.242"/>
                    <measurement group_id="O2" value="31.515" spread="3.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C17 D1 (n= 78, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.564" spread="4.695"/>
                    <measurement group_id="O2" value="31.567" spread="3.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C18 D1 (n= 71, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.380" spread="4.752"/>
                    <measurement group_id="O2" value="31.107" spread="4.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C19 D1 (n= 57, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.737" spread="4.414"/>
                    <measurement group_id="O2" value="31.417" spread="3.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C20 D1 (n= 45, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.844" spread="4.527"/>
                    <measurement group_id="O2" value="30.762" spread="4.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C21 D1 (n= 36, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.889" spread="3.115"/>
                    <measurement group_id="O2" value="30.056" spread="4.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C22 D1 (n= 23, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.696" spread="3.081"/>
                    <measurement group_id="O2" value="31.000" spread="3.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C23 D1 (n= 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.357" spread="3.388"/>
                    <measurement group_id="O2" value="31.143" spread="4.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment (n= 72, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.556" spread="5.487"/>
                    <measurement group_id="O2" value="26.786" spread="5.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (n= 41, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.805" spread="6.373"/>
                    <measurement group_id="O2" value="26.769" spread="6.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): Second-Line Participants</title>
        <description>FKSI-DRS: subset of FKSI which is FACTKidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).</description>
        <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)</time_frame>
        <population>FAS previously-treated Asian population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): Second-Line Participants</title>
          <description>FKSI-DRS: subset of FKSI which is FACTKidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).</description>
          <population>FAS previously-treated Asian population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1 D1 (n= 134, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.020" spread="3.986"/>
                    <measurement group_id="O2" value="31.489" spread="4.538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (n= 127, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.600" spread="3.892"/>
                    <measurement group_id="O2" value="30.682" spread="3.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (n= 124, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.645" spread="3.681"/>
                    <measurement group_id="O2" value="30.965" spread="3.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (n= 116, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.103" spread="4.558"/>
                    <measurement group_id="O2" value="30.679" spread="3.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (n= 111, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.676" spread="4.271"/>
                    <measurement group_id="O2" value="31.063" spread="3.629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C6 D1 (n= 108, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.731" spread="3.973"/>
                    <measurement group_id="O2" value="31.439" spread="4.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (n= 100, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.920" spread="4.373"/>
                    <measurement group_id="O2" value="30.632" spread="4.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C8 D1 (n= 89, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.966" spread="4.144"/>
                    <measurement group_id="O2" value="30.703" spread="5.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (n= 82, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.012" spread="3.783"/>
                    <measurement group_id="O2" value="30.667" spread="4.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C10 D1 (n= 74, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.986" spread="4.133"/>
                    <measurement group_id="O2" value="30.926" spread="4.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (n= 66, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.212" spread="4.033"/>
                    <measurement group_id="O2" value="32.045" spread="3.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C12 D1 (n= 59, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.356" spread="3.443"/>
                    <measurement group_id="O2" value="32.000" spread="3.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C13 D1 (n= 55, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.418" spread="3.775"/>
                    <measurement group_id="O2" value="32.100" spread="2.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C14 D1 (n= 50, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.100" spread="3.321"/>
                    <measurement group_id="O2" value="32.800" spread="2.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C15 D1 (n= 44, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.000" spread="2.861"/>
                    <measurement group_id="O2" value="32.769" spread="2.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C16 D1 (n= 38, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.921" spread="3.372"/>
                    <measurement group_id="O2" value="33.167" spread="2.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C17 D1 (n= 33, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.061" spread="3.344"/>
                    <measurement group_id="O2" value="32.800" spread="2.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C18 D1 (n= 29, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.931" spread="3.116"/>
                    <measurement group_id="O2" value="32.625" spread="2.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C19 D1 (n= 22, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.364" spread="2.341"/>
                    <measurement group_id="O2" value="32.429" spread="4.429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C20 D1 (n= 21, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.905" spread="2.998"/>
                    <measurement group_id="O2" value="33.500" spread="2.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C21 D1 (n= 16, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.125" spread="2.473"/>
                    <measurement group_id="O2" value="33.500" spread="2.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment (n= 37, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.216" spread="5.662"/>
                    <measurement group_id="O2" value="29.519" spread="4.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (n= 13, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.692" spread="4.366"/>
                    <measurement group_id="O2" value="27.500" spread="6.762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: First-Line Participants</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
        <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)</time_frame>
        <population>FAS treatment-naive population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: First-Line Participants</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
          <population>FAS treatment-naive population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1 D1 (n= 183, 94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.710" spread="0.254"/>
                    <measurement group_id="O2" value="0.712" spread="0.272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (n= 175, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.709" spread="0.214"/>
                    <measurement group_id="O2" value="0.693" spread="0.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (n= 163, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.694" spread="0.251"/>
                    <measurement group_id="O2" value="0.687" spread="0.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (n= 156, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.696" spread="0.235"/>
                    <measurement group_id="O2" value="0.668" spread="0.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (n= 153, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.708" spread="0.221"/>
                    <measurement group_id="O2" value="0.673" spread="0.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C6 D1 (n= 140, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.683" spread="0.263"/>
                    <measurement group_id="O2" value="0.641" spread="0.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (n= 139, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.685" spread="0.225"/>
                    <measurement group_id="O2" value="0.676" spread="0.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C8 D1 (n= 131, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.678" spread="0.274"/>
                    <measurement group_id="O2" value="0.717" spread="0.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (n= 126, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.704" spread="0.239"/>
                    <measurement group_id="O2" value="0.729" spread="0.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C10 D1 (n= 122, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.682" spread="0.277"/>
                    <measurement group_id="O2" value="0.723" spread="0.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (n= 114, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.698" spread="0.260"/>
                    <measurement group_id="O2" value="0.748" spread="0.199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C12 D1 (n= 105, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.708" spread="0.227"/>
                    <measurement group_id="O2" value="0.742" spread="0.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C13 D1 (n= 99, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.708" spread="0.253"/>
                    <measurement group_id="O2" value="0.761" spread="0.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C14 D1 (n= 95, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.703" spread="0.260"/>
                    <measurement group_id="O2" value="0.731" spread="0.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C15 D1 (n= 85, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.689" spread="0.269"/>
                    <measurement group_id="O2" value="0.755" spread="0.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C16 D1 (n= 82, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.702" spread="0.244"/>
                    <measurement group_id="O2" value="0.775" spread="0.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C17 D1 (n= 78, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.706" spread="0.250"/>
                    <measurement group_id="O2" value="0.738" spread="0.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C18 D1 (n= 71, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.699" spread="0.259"/>
                    <measurement group_id="O2" value="0.777" spread="0.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C19 D1 (n= 56, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.713" spread="0.256"/>
                    <measurement group_id="O2" value="0.762" spread="0.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C20 D1 (n= 45, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.699" spread="0.261"/>
                    <measurement group_id="O2" value="0.710" spread="0.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C21 D1 (n= 36, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.712" spread="0.232"/>
                    <measurement group_id="O2" value="0.702" spread="0.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C22 D1 (n= 23, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.737" spread="0.255"/>
                    <measurement group_id="O2" value="0.774" spread="0.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C23 D1 (n= 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.736" spread="0.275"/>
                    <measurement group_id="O2" value="0.789" spread="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment (n= 70, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.635" spread="0.268"/>
                    <measurement group_id="O2" value="0.588" spread="0.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (n= 41, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.545" spread="0.434"/>
                    <measurement group_id="O2" value="0.618" spread="0.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: Second-Line Participants</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
        <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)</time_frame>
        <population>FAS previously-treated Asian population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: Second-Line Participants</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
          <population>FAS previously-treated Asian population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1 D1 (n= 134, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.812" spread="0.225"/>
                    <measurement group_id="O2" value="0.831" spread="0.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (n= 127, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.769" spread="0.218"/>
                    <measurement group_id="O2" value="0.754" spread="0.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (n= 124, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.772" spread="0.206"/>
                    <measurement group_id="O2" value="0.755" spread="0.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (n= 116, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.737" spread="0.272"/>
                    <measurement group_id="O2" value="0.759" spread="0.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (n= 111, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.780" spread="0.203"/>
                    <measurement group_id="O2" value="0.768" spread="0.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C6 D1 (n= 108, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.767" spread="0.251"/>
                    <measurement group_id="O2" value="0.753" spread="0.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (n= 100, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.762" spread="0.252"/>
                    <measurement group_id="O2" value="0.768" spread="0.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C8 D1 (n= 89, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.758" spread="0.241"/>
                    <measurement group_id="O2" value="0.733" spread="0.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (n= 82, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.796" spread="0.203"/>
                    <measurement group_id="O2" value="0.794" spread="0.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C10 D1 (n= 74, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.768" spread="0.243"/>
                    <measurement group_id="O2" value="0.820" spread="0.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (n= 66, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.792" spread="0.210"/>
                    <measurement group_id="O2" value="0.848" spread="0.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C12 D1 (n= 59, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.797" spread="0.201"/>
                    <measurement group_id="O2" value="0.837" spread="0.157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C13 D1 (n= 55, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.786" spread="0.217"/>
                    <measurement group_id="O2" value="0.814" spread="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C14 D1 (n= 50, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.833" spread="0.162"/>
                    <measurement group_id="O2" value="0.871" spread="0.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C15 D1 (n= 44, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.819" spread="0.151"/>
                    <measurement group_id="O2" value="0.829" spread="0.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C16 D1 (n= 38, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.811" spread="0.186"/>
                    <measurement group_id="O2" value="0.828" spread="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C17 D1 (n= 33, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.834" spread="0.158"/>
                    <measurement group_id="O2" value="0.865" spread="0.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C18 D1 (n= 29, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.830" spread="0.164"/>
                    <measurement group_id="O2" value="0.829" spread="0.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C19 D1 (n= 22, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.830" spread="0.148"/>
                    <measurement group_id="O2" value="0.861" spread="0.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C20 D1 (n= 21, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.832" spread="0.163"/>
                    <measurement group_id="O2" value="0.923" spread="0.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C21 D1 (n= 16, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.859" spread="0.155"/>
                    <measurement group_id="O2" value="0.852" spread="0.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment (n= 37, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.582" spread="0.406"/>
                    <measurement group_id="O2" value="0.623" spread="0.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (n= 13, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.429" spread="0.358"/>
                    <measurement group_id="O2" value="0.418" spread="0.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): First-Line Participants</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.</description>
        <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)</time_frame>
        <population>FAS treatment-naive population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (First-line Participants)</title>
            <description>Participants with no prior systemic first-line therapy received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): First-Line Participants</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.</description>
          <population>FAS treatment-naive population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1 D1 (n= 182, 94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.181" spread="19.641"/>
                    <measurement group_id="O2" value="72.362" spread="16.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (n= 175, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.714" spread="16.583"/>
                    <measurement group_id="O2" value="72.422" spread="14.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (n= 165, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.006" spread="16.971"/>
                    <measurement group_id="O2" value="71.241" spread="16.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (n= 156, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.179" spread="16.980"/>
                    <measurement group_id="O2" value="72.086" spread="14.904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (n= 153, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.451" spread="18.237"/>
                    <measurement group_id="O2" value="73.615" spread="14.665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C6 D1 (n= 141, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.574" spread="18.929"/>
                    <measurement group_id="O2" value="69.944" spread="17.535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (n= 139, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.050" spread="18.967"/>
                    <measurement group_id="O2" value="73.923" spread="13.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C8 D1 (n= 131, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.031" spread="19.081"/>
                    <measurement group_id="O2" value="73.183" spread="16.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (n= 126, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.690" spread="18.789"/>
                    <measurement group_id="O2" value="73.780" spread="16.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C10 D1 (n= 122, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.910" spread="19.354"/>
                    <measurement group_id="O2" value="72.400" spread="18.814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (n= 114, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.763" spread="18.174"/>
                    <measurement group_id="O2" value="72.271" spread="18.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C12 D1 (n= 105, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.610" spread="18.275"/>
                    <measurement group_id="O2" value="75.295" spread="17.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C13 D1 (n= 99, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.030" spread="18.348"/>
                    <measurement group_id="O2" value="75.432" spread="17.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C14 D1 (n= 95, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.147" spread="17.546"/>
                    <measurement group_id="O2" value="75.108" spread="18.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C15 D1 (n= 85, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.494" spread="17.938"/>
                    <measurement group_id="O2" value="74.405" spread="17.650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C16 D1 (n= 82, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.878" spread="18.289"/>
                    <measurement group_id="O2" value="75.818" spread="17.716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C17 D1 (n= 78, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.090" spread="17.717"/>
                    <measurement group_id="O2" value="74.333" spread="18.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C18 D1 (n= 71, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.817" spread="17.288"/>
                    <measurement group_id="O2" value="75.571" spread="18.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C19 D1 (n= 56, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.089" spread="18.169"/>
                    <measurement group_id="O2" value="75.125" spread="20.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C20 D1 (n= 45, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.244" spread="17.044"/>
                    <measurement group_id="O2" value="74.190" spread="20.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C21 D1 (n= 36, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.694" spread="11.918"/>
                    <measurement group_id="O2" value="70.500" spread="21.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C22 D1 (n= 23, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.000" spread="12.544"/>
                    <measurement group_id="O2" value="73.917" spread="15.900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C23 D1 (n= 14, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.143" spread="12.697"/>
                    <measurement group_id="O2" value="72.571" spread="14.820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment (n= 71, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.254" spread="19.495"/>
                    <measurement group_id="O2" value="67.048" spread="22.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (n= 41, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.195" spread="20.366"/>
                    <measurement group_id="O2" value="64.885" spread="19.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): Second-Line Participants</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.</description>
        <time_frame>Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)</time_frame>
        <population>FAS previously-treated Asian population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Axitinib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Second-line Participants)</title>
            <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): Second-Line Participants</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.</description>
          <population>FAS previously-treated Asian population. Here N (Number of participants analyzed) signifies those participants who were evaluable for this measure and n signifies those participants evaluated for this measure at specific time point for each group respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C1 D1 (n= 134, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.799" spread="13.351"/>
                    <measurement group_id="O2" value="82.058" spread="14.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C2 D1 (n= 127, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.102" spread="13.895"/>
                    <measurement group_id="O2" value="78.231" spread="15.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3 D1 (n= 124, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.895" spread="13.387"/>
                    <measurement group_id="O2" value="80.534" spread="16.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 D1 (n= 116, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.138" spread="13.508"/>
                    <measurement group_id="O2" value="81.245" spread="14.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5 D1 (n= 111, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.018" spread="12.829"/>
                    <measurement group_id="O2" value="80.250" spread="15.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C6 D1 (n= 108, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.222" spread="13.793"/>
                    <measurement group_id="O2" value="80.829" spread="15.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7 D1 (n= 100, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.900" spread="13.287"/>
                    <measurement group_id="O2" value="80.868" spread="16.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C8 D1 (n= 89, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.382" spread="12.636"/>
                    <measurement group_id="O2" value="81.000" spread="14.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C9 D1 (n= 82, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.171" spread="11.260"/>
                    <measurement group_id="O2" value="83.788" spread="10.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C10 D1 (n= 74, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.041" spread="13.042"/>
                    <measurement group_id="O2" value="82.778" spread="11.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C11 D1 (n= 66, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.136" spread="14.231"/>
                    <measurement group_id="O2" value="83.000" spread="11.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C12 D1 (n= 59, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.305" spread="13.211"/>
                    <measurement group_id="O2" value="83.500" spread="12.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C13 D1 (n= 55, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.927" spread="17.317"/>
                    <measurement group_id="O2" value="83.300" spread="11.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C14 D1 (n= 50, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.520" spread="10.831"/>
                    <measurement group_id="O2" value="86.667" spread="8.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C15 D1 (n= 44, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.841" spread="11.783"/>
                    <measurement group_id="O2" value="86.462" spread="8.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C16 D1 (n= 38, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.579" spread="10.391"/>
                    <measurement group_id="O2" value="86.083" spread="8.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C17 D1 (n= 33, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.424" spread="10.866"/>
                    <measurement group_id="O2" value="84.300" spread="10.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C18 D1 (n= 29, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.586" spread="13.605"/>
                    <measurement group_id="O2" value="83.125" spread="8.839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C19 D1 (n= 22, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.500" spread="8.684"/>
                    <measurement group_id="O2" value="82.143" spread="11.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C20 D1 (n= 21, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.333" spread="8.679"/>
                    <measurement group_id="O2" value="86.000" spread="9.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C21 D1 (n= 16, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.313" spread="9.741"/>
                    <measurement group_id="O2" value="84.167" spread="9.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment (n= 37, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.568" spread="17.934"/>
                    <measurement group_id="O2" value="74.741" spread="17.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (n= 13, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.154" spread="20.760"/>
                    <measurement group_id="O2" value="64.333" spread="25.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Week 107</time_frame>
      <desc>Same event may appear as both AE and SAE. However, what is presented are distinct events. Event may be categorized as serious in 1 subject and nonserious in another subject, or 1 subject may have experienced both a serious and nonserious event during the study. Participants at risk = 189, 96, 135, 69 for each arm group, respectively.</desc>
      <group_list>
        <group group_id="E1">
          <title>Axitinib (First-line Participants)</title>
          <description>Participants with no prior systemic first-line therapy received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Sorafenib (First-line Participants)</title>
          <description>Participants with no prior systemic first-line therapy received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Axitinib (Second-line Participants)</title>
          <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Sorafenib (Second-line Participants)</title>
          <description>Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received sorafenib tablet at a starting dose of 400 mg orally twice daily, dose adjustment was done based on the tolerability, as per investigators discretion. Study medication was administered in cycles of 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Periproctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pyopneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pericoronitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cardiac neoplasm unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Demyelinating polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Aorto-duodenal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="131" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The objective of the statistical analysis for secondary endpoints was to summarize data using descriptive statistics without performing any hypothesis testing.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

